FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy

Published by W Butcher on

The U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin- dependent kinase 4/6, a type of enzyme. 

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.